CPRX
Catalyst Pharmaceuticals, Inc. NASDAQ Listed Nov 8, 2006$31.16
Mkt Cap $3.8B
52w Low $19.05
89.7% of range
52w High $32.56
50d MA $25.34
200d MA $22.84
P/E (TTM)
16.4x
EV/EBITDA
6.7x
P/B
3.7x
Debt/Equity
0.0x
ROE
22.5%
P/FCF
13.7x
RSI (14)
—
ATR (14)
—
Beta
0.66
50d MA
$25.34
200d MA
$22.84
Avg Volume
1.3M
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
355 Alhambra Circle · Coral Gables, FL 33134 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 25, 2026 | AMC | 0.42 | 0.68 | +61.9% | 24.86 | -1.5% | +0.1% | -7.2% | -3.9% | -3.8% | -0.7% | — |
| Nov 5, 2025 | AMC | 0.51 | 0.68 | +33.3% | 21.38 | +5.6% | -1.8% | +0.0% | +0.8% | +8.0% | +6.5% | — |
| Aug 6, 2025 | AMC | 0.58 | 0.68 | +17.2% | 21.79 | -0.5% | -9.9% | -8.9% | -9.7% | -6.7% | -7.3% | — |
| May 7, 2025 | AMC | 0.53 | 0.68 | +28.3% | 23.46 | -1.2% | -3.0% | -0.4% | +1.6% | +0.8% | -0.3% | — |
| Feb 26, 2025 | AMC | 0.32 | 0.70 | +118.8% | 20.58 | +8.5% | +5.2% | +11.2% | +8.5% | +7.4% | +6.4% | — |
| Nov 6, 2024 | AMC | 0.49 | 0.57 | +16.3% | 22.71 | +6.6% | +2.4% | +5.4% | +3.3% | +1.5% | +0.4% | — |
| Aug 7, 2024 | AMC | 0.42 | 0.56 | +33.3% | 16.23 | +7.8% | +12.8% | +13.9% | +18.9% | +20.7% | +18.5% | — |
| May 8, 2024 | AMC | 0.34 | 0.38 | +11.8% | 14.72 | +1.0% | +6.3% | +8.3% | +10.2% | +12.0% | +13.2% | — |
| Feb 28, 2024 | AMC | 0.48 | 0.53 | +10.4% | 14.56 | +11.9% | +10.1% | +16.8% | +14.6% | +11.7% | +8.9% | — |
| Nov 8, 2023 | AMC | -0.24 | -0.24 | +0.0% | 12.54 | +6.8% | -1.8% | +2.5% | +0.7% | +6.7% | +8.9% | — |
| Aug 9, 2023 | AMC | 0.25 | 0.33 | +32.0% | 14.12 | +6.4% | +6.4% | +5.4% | +5.2% | +6.1% | +4.4% | — |
| May 10, 2023 | AMC | 0.32 | 0.26 | -18.8% | 17.51 | +0.0% | -19.2% | -23.2% | -25.0% | -28.6% | -28.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 3 | Citigroup | Maintains | Buy → Buy | — | $23.88 | $23.88 | +0.0% | +0.2% | +3.4% | +1.8% | +1.5% | +3.8% |
| Nov 7 | Citigroup | Maintains | Buy → Buy | — | $20.99 | $21.27 | +1.3% | +1.9% | +2.7% | +10.1% | +8.5% | +9.7% |
| Mar 3 | Baird | Maintains | Outperform → Outperform | — | $22.89 | $22.89 | +0.0% | -2.5% | -3.5% | -4.4% | -5.3% | -4.1% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.66 | $21.93 | +1.2% | +5.7% | +3.0% | +2.0% | +1.1% | +0.0% |
| Feb 27 | Stephens & Co. | Maintains | Overweight → Overweight | — | $20.58 | $22.32 | +8.5% | +5.2% | +11.2% | +8.5% | +7.4% | +6.4% |
| Jan 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.80 | $22.85 | +0.2% | -3.9% | -2.6% | -2.7% | +1.1% | -0.6% |
| Jan 9 | BofA Securities | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Nov 11 | Truist | Maintains | Buy → Buy | — | $23.93 | $24.10 | +0.7% | -2.0% | -3.7% | -4.7% | -9.4% | -13.9% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.25 | $23.50 | +1.1% | +2.9% | +0.9% | -0.9% | -1.9% | -6.7% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.48 | $18.83 | +1.9% | +4.4% | +6.0% | +4.1% | +7.7% | +7.5% |
| Aug 9 | Citigroup | Maintains | Buy → Buy | — | $18.30 | $18.45 | +0.8% | +1.0% | +5.5% | +7.0% | +5.1% | +8.8% |
| Aug 9 | Truist | Maintains | Buy → Buy | — | $18.30 | $18.45 | +0.8% | +1.0% | +5.5% | +7.0% | +5.1% | +8.8% |
| Jun 6 | Oppenheimer | Maintains | Outperform → Outperform | — | $16.31 | $16.20 | -0.7% | -3.4% | -4.2% | -4.2% | -4.6% | -5.3% |
| Jun 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.17 | $16.27 | +0.6% | +0.1% | -0.8% | +0.9% | -2.5% | -3.4% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.65 | $15.83 | +1.2% | +1.9% | +3.6% | +5.4% | +6.5% | +4.8% |
| Mar 27 | Oppenheimer | Maintains | Outperform → Outperform | — | $15.75 | $15.90 | +1.0% | +3.3% | +1.2% | -0.1% | -3.1% | -1.7% |
| Mar 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $16.62 | $16.60 | -0.1% | -5.4% | -4.6% | -5.2% | -2.1% | -4.1% |
| Mar 14 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $16.62 | $17.02 | +2.4% | -2.6% | -3.3% | -3.2% | -1.4% | +1.7% |
| Mar 1 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $16.03 | $16.20 | +1.1% | +6.1% | +4.1% | +1.5% | -1.1% | +3.8% |
| Mar 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.03 | $16.20 | +1.1% | +6.1% | +4.1% | +1.5% | -1.1% | +3.8% |
| Aug 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $14.60 | $14.59 | -0.1% | -1.2% | -3.2% | -5.1% | -2.5% | -2.7% |
| Aug 11 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $15.02 | $15.08 | +0.4% | -0.9% | -1.1% | -0.3% | -1.9% | -5.2% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.02 | $15.08 | +0.4% | -0.9% | -1.1% | -0.3% | -1.9% | -5.2% |
| Jul 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.68 | $13.73 | +0.4% | -0.1% | -1.0% | -2.0% | -2.7% | -2.5% |
| Jun 21 | Truist | Maintains | Buy → Buy | — | $12.62 | $12.85 | +1.8% | +5.0% | +4.0% | +4.2% | +2.2% | +4.0% |
| Jun 21 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $12.62 | $12.85 | +1.8% | +5.0% | +4.0% | +4.2% | +2.2% | +4.0% |
| Jun 20 | Truist | Maintains | Buy → Buy | — | $12.20 | $12.14 | -0.5% | +3.4% | +8.6% | +7.6% | +7.8% | +5.7% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.15 | $14.16 | +0.1% | -4.9% | -7.1% | -11.6% | -11.4% | -13.8% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.92 | $15.96 | +0.3% | +3.0% | +3.8% | +1.8% | +0.6% | +1.3% |
| Jan 19 | Truist | Maintains | Buy → Buy | — | $20.43 | $20.31 | -0.6% | -0.8% | +1.8% | -27.8% | -21.1% | -18.1% |
| Dec 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.60 | $18.92 | +1.7% | +4.8% | +4.0% | +2.2% | -0.1% | -2.5% |
| Dec 21 | Truist | Maintains | Buy → Buy | — | $18.60 | $18.92 | +1.7% | +4.8% | +4.0% | +2.2% | -0.1% | -2.5% |
| Dec 20 | Piper Sandler | Maintains | Overweight → Overweight | — | $16.41 | $16.80 | +2.4% | +13.3% | +18.8% | +17.9% | +15.8% | +13.3% |
| Aug 24 | Roth Capital | Downgrade | Buy → Neutral | — | $14.91 | $14.47 | -3.0% | -6.3% | -3.8% | -6.0% | -5.3% | -7.0% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.13 | $13.10 | -0.2% | +1.8% | +5.9% | +8.4% | +6.4% | +4.6% |
| Aug 11 | Truist | Maintains | Buy → Buy | — | $13.13 | $13.10 | -0.2% | +1.8% | +5.9% | +8.4% | +6.4% | +4.6% |
| Feb 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.54 | $6.56 | +0.3% | +6.9% | +12.4% | +13.3% | +21.4% | +15.9% |
| Mar 18 | Roth Capital | Maintains | Buy → Buy | — | $4.23 | $4.24 | +0.2% | -0.5% | +3.3% | +10.9% | +10.4% | +1.4% |
| Aug 12 | Truist | Maintains | Buy → Buy | — | $3.34 | $3.45 | +3.3% | +0.6% | +2.1% | +3.9% | +10.5% | +9.0% |
| May 13 | SunTrust Robinson Humphrey | Maintains | Buy → Buy | — | $4.58 | $4.63 | +1.0% | -4.4% | -7.1% | -0.8% | -0.8% | -6.2% |
| Feb 14 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $4.77 | $4.89 | +2.5% | +0.0% | +7.5% | +7.8% | +9.0% | +9.2% |
| Dec 13 | Piper Sandler | Maintains | Overweight → Overweight | — | $2.40 | $2.52 | +5.0% | +2.5% | -2.5% | -2.5% | +1.2% | -6.7% |
| Dec 13 | PiperJaffray | Maintains | Overweight → Overweight | — | $2.40 | $2.52 | +5.0% | +2.5% | -2.5% | -2.5% | +1.2% | -6.7% |
| Nov 29 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.13 | $2.98 | -4.8% | -11.5% | -19.0% | -23.8% | -26.5% | -28.8% |
| Sep 21 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.14 | $3.17 | +1.0% | +0.3% | +9.6% | +11.1% | +18.2% | +19.7% |
| Jul 13 | Oppenheimer | Maintains | Outperform → Outperform | — | $3.20 | $3.46 | +8.1% | +2.2% | +0.9% | -0.9% | -3.8% | -3.8% |
| Oct 5 | PiperJaffray | Upgrade | Neutral → Overweight | — | $1.12 | $1.28 | +14.3% | +30.4% | +24.1% | +21.4% | +17.9% | +11.6% |
| Oct 5 | Piper Sandler | Upgrade | Neutral → Overweight | — | $1.12 | $1.28 | +14.3% | +30.4% | +24.1% | +21.4% | +17.9% | +11.6% |
| Apr 26 | PiperJaffray | Downgrade | Overweight → Neutral | — | $1.24 | $0.55 | -55.6% | -49.2% | -49.2% | -48.8% | -45.2% | -46.5% |
| Apr 26 | Piper Sandler | Downgrade | Overweight → Neutral | — | $1.24 | $0.55 | -55.6% | -49.2% | -49.2% | -48.8% | -45.2% | -46.5% |
No insider trades available.
8-K
Catalyst Pharmaceuticals, Inc. -- 8-K Filing
Catalyst Pharmaceuticals' merger agreement provides cash consideration for in-the-money stock options while canceling out-of-the-money options, affecting shareholder and optionholder economics in the transaction.
May 7
8-K
Unknown — 8-K Filing
This appears to be a technical correction to a previously filed 8-K, suggesting no material business developments were omitted—investors should review the original filing for substantive information.
Mar 19
8-K
Unknown — 8-K Filing
I cannot write a meaningful analyst sentence about this filing because the 8-K summary provided contains only technical XBRL schema metadata rather than actual business event disclosures; an investor cannot assess stock impact without substantive filing content.
Mar 18
8-K
Catalyst Pharmaceutical Inc. -- 8-K Filing
Catalyst Pharmaceutical (CPRX) projects 2026 revenues of $615-645 million with promoted product revenue growth exceeding 20%, demonstrating confidence in its FIRDAPSE and AGAMREE drug franchises.
Feb 25
Data updated apr 25, 2026 2:55am
· Source: massive.com